Please assess the completion status of the following clinical trial:

Trial Title: Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with AML with or without prior history of myelodysplastic syndrome based on the World Health Organization criteria at the following stages:~  * First morphologic complete remission (CR)~ * Second morphologic CR~* If prior history of central nervous system (CNS) involvement, no evidence of active CNS leukemia during the pre-transplant evaluation (no evidence of leukemic blasts in cerebrospinal fluid)~* First or second CR was achieved after no more than two cycles of induction (or re-induction for patients in second CR) chemotherapy~* No more than 6 months elapsed from documentation of CR to transplant for patients in first CR, or 3 months for patients in second CR.~* A 6/6 HLA antigen (A, B, DRB1)-compatible sibling donor; the match may be determined at serologic level for HLA-A and HLA-B loci; DRB1 must be matched at least at low-resolution using DNA typing techniques; HLA-C will be typed at the serologic level, but not included in the match algorithm~* Karnofsky performance status greater than 70%~* Life expectancy greater than 8 weeks~* Diffusing capacity of the lung for carbon monoxide (DLCO) of at least 40% (corrected for hemoglobin) with no symptomatic pulmonary disease~* Left ventricular ejection fraction (LVEF) by Multi Gated Acquisition Scan (MUGA) or echocardiogram greater than 40%~* Serum creatinine greater than 2 mg/dL, bilirubin greater than 2 mg/dL, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at least 3 times the upper limit of normal at time of enrollment~* Willingness of both the patient and the donor to participate~Exclusion Criteria:~* M3-AML (acute promyelocytic leukemia) in first CR~* Acute leukemia following blast transformation of prior chronic myelogenous leukemia (CML) or other myeloproliferative disease~* M4Eo-AML with inv 16 in first CR~* AML with t(8;21) in first CR~* Participation in other clinical trials that involve investigational drugs or devices except with permission from the Medical Monitor~* Evidence of active Hepatitis B or C infection or evidence of cirrhosis~* HIV positive~* Uncontrolled diabetes mellitus~* If proven or probable invasive fungal infection, infection must be controlled; patients may be on prophylactic anti-fungal agents, but are not permitted to be on anti-fungal agents for therapeutic purposes (i.e., active treatment for disease)~* Uncontrolled viral or bacterial infection (currently taking medication without clinical improvement)~* Documented allergy to iron dextran or murine proteins~* Pregnant or breastfeeding; women of childbearing age must avoid becoming pregnant while in the study~* Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CD34+ selection with CliniMACS device (Type: EXPERIMENTAL): T cell depletion using Miltenyi device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete